Analysts predict that Reata Pharmaceuticals Inc (NASDAQ:RETA) will post ($0.97) earnings per share for the current quarter, according to Zacks. Four analysts have provided estimates for Reata Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.03) and the highest estimate coming in at ($0.94). Reata Pharmaceuticals posted earnings per share of $0.15 during the same quarter last year, which indicates a negative year-over-year growth rate of 746.7%. The firm is expected to announce its next earnings results on Tuesday, May 14th.
According to Zacks, analysts expect that Reata Pharmaceuticals will report full year earnings of ($4.56) per share for the current financial year, with EPS estimates ranging from ($4.93) to ($4.12). For the next fiscal year, analysts expect that the firm will report earnings of ($3.00) per share, with EPS estimates ranging from ($4.79) to ($0.35). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Reata Pharmaceuticals.
Reata Pharmaceuticals (NASDAQ:RETA) last released its quarterly earnings results on Thursday, February 28th. The company reported ($0.86) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.02) by $0.16. The firm had revenue of $8.45 million for the quarter, compared to analyst estimates of $6.60 million.
RETA has been the topic of several research analyst reports. BidaskClub lowered shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. ValuEngine upgraded shares of Reata Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 1st. Finally, Cantor Fitzgerald set a $100.00 target price on shares of Reata Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, February 20th. Two analysts have rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. Reata Pharmaceuticals has a consensus rating of “Buy” and an average target price of $100.33.
In other news, insider Elaine Castellanos sold 3,588 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $102.00, for a total value of $365,976.00. Following the transaction, the insider now directly owns 5,726 shares of the company’s stock, valued at $584,052. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Keith Wayne Ward sold 4,150 shares of the firm’s stock in a transaction dated Thursday, January 31st. The stock was sold at an average price of $76.70, for a total transaction of $318,305.00. Following the completion of the transaction, the insider now directly owns 12,770 shares in the company, valued at $979,459. The disclosure for this sale can be found here. In the last quarter, insiders sold 58,377 shares of company stock worth $5,211,691. Company insiders own 31.69% of the company’s stock.
Large investors have recently bought and sold shares of the company. Alliancebernstein L.P. lifted its stake in shares of Reata Pharmaceuticals by 31.8% in the third quarter. Alliancebernstein L.P. now owns 23,600 shares of the company’s stock worth $1,930,000 after buying an additional 5,700 shares in the last quarter. UBS Oconnor LLC raised its stake in shares of Reata Pharmaceuticals by 39.6% during the fourth quarter. UBS Oconnor LLC now owns 17,178 shares of the company’s stock valued at $964,000 after purchasing an additional 4,874 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Reata Pharmaceuticals by 75.1% during the third quarter. Vanguard Group Inc. now owns 1,187,632 shares of the company’s stock valued at $97,101,000 after purchasing an additional 509,326 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Reata Pharmaceuticals by 276.8% during the third quarter. Tower Research Capital LLC TRC now owns 1,398 shares of the company’s stock valued at $114,000 after purchasing an additional 1,027 shares in the last quarter. Finally, Sofinnova Investments Inc. bought a new stake in shares of Reata Pharmaceuticals during the fourth quarter valued at about $8,863,000. 53.60% of the stock is currently owned by hedge funds and other institutional investors.
RETA stock traded down $3.52 during midday trading on Wednesday, hitting $79.00. 44,482 shares of the stock traded hands, compared to its average volume of 238,976. The firm has a market cap of $2.46 billion, a PE ratio of -27.53 and a beta of 3.12. The company has a debt-to-equity ratio of 5.23, a quick ratio of 6.12 and a current ratio of 6.12. Reata Pharmaceuticals has a 1-year low of $20.91 and a 1-year high of $104.53.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.
Featured Story: How to Trade Using Analysts Ratings
Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.